What Dologesic Treats: Main Uses and Benefits

The primary role of Dologesic is to provide supportive symptomatic relief in situations where standard non-opioid medications do not offer sufficient support. This combination is considered relevant for managing acute pain when the severity suggests a need for supportive relief beyond non-opioid options.

Relief for Moderate to Moderately Severe Pain

It is commonly used across conditions presenting with acute or disruptive episodes, such as postoperative pain following surgical procedures, or for managing pain associated with physical discomfort and the flare-ups of chronic conditions like osteoarthritis and recurrent low back pain. It is relevant in contexts where additional support for symptom management is appropriate, generally focusing on pain manifestations categorized as moderate or moderately severe. It provides symptomatic relief that may assist patients in coping more steadily with difficult episodes.

“This medication is applied in scenarios where additional management of discomfort is required, contributing to improved comfort during symptomatic periods.”

Quick Fact: Relief for Moderate to Moderately Severe Pain

Key Therapeutic Domains

Dologesic is relevant in contexts involving increased discomfort or tension and is used for managing symptom clusters that may become intense or disruptive. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptoms that interfere with daily functioning and assisting with maintaining functional stability.

Regulatory References

1. DailyMed NLM/NIH Overview of Tramadol/Acetaminophen

This information pertains to Dologesic formulations containing acetaminophen and an antihistamine (such as Phenyltoloxamine), based on official regulatory labeling.

Contraindications and Exclusions

Dologesic must not be used by the following groups:

Conditional Use and Restrictions

Eligibility is restricted or conditional for certain patients, who must consult a healthcare professional before use:

• Liver Disease or Alcohol Use: Individuals with liver disease or those who consume three or more alcoholic drinks daily must seek advice due to the increased risk of liver toxicity from the acetaminophen component.
• Comorbidities: Consult a doctor if you have conditions such as glaucoma, heart disease, high blood pressure, asthma, COPD, or difficulty urinating (e.g., due to an enlarged prostate).
• Pregnancy/Lactation: Pregnant or breastfeeding individuals must ask a health professional before use, as safety is not established for the combination in these physiological states.

Dologesic’s interaction profile is primarily defined by regulatory-mandated restrictions against combining it with substances that increase central nervous system (CNS) effects or significantly alter its metabolism.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. A mandatory 14-day separation period is required after discontinuation of an MAOI before Dologesic administration can begin. The combination is also contraindicated with any other products containing tramadol or acetaminophen to mitigate the risk of overdose and organ toxicity. Use is formally restricted in populations with severe hepatic or renal impairment.

Documented Pharmacodynamic and Metabolic Interactions

The official labeling notes several clinically significant pharmacodynamic interactions. Combining Dologesic with other CNS depressants, including alcohol and benzodiazepines, may lead to profound sedation and respiratory depression. Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) increases the officially recognized risk of developing Serotonin Syndrome.

From a metabolic standpoint, co-administration with inhibitors or inducers of CYP2D6 or CYP3A4 results in complex pharmacokinetic effects on the resulting plasma concentrations of tramadol and its M1 metabolite. Co-administration with Warfarin or other Coumarin derivatives has been associated with changes in prothrombin time and INR, which may increase bleeding risk.

Dologesic functions as a selective non-steroidal anti-inflammatory drug (NSAID) by targeting the Cyclooxygenase-2 (COX-2) enzyme. The compound exhibits a selective inhibitory interaction with the active site of COX-2, which is an inducible enzyme expressed primarily at sites of cellular signaling activation. This molecular interaction blocks the cyclooxygenase activity, thereby interrupting the arachidonic acid cascade. The direct consequence of this binding is a substantial decrease in the biosynthesis and release of pro-inflammatory prostaglandins, specifically prostaglandin E2 ( PGE2). By attenuating the PGE2 cascade, Dologesic modulates cellular responses and key signaling pathways associated with localized tissue activation. This action results in the downstream modification of various physiological processes, including the regulation of vascular permeability and local cellular communication.

The administration of Dologesic is based on the formulation of the fixed-dose combination oral tablet (37.5 mg tramadol / 325 mg acetaminophen). The medicine is designated for short-term administration, with treatment generally limited to five days or less.

Standard Dosing and Frequency

The standard adult regimen establishes the initial administration as two tablets. Subsequent doses are taken only as needed for symptomatic use, constrained by a mandatory minimum interval of six hours between doses. The maximum permitted daily intake is strictly limited to eight tablets in any 24-hour period. It is a procedural requirement that the tablets must be swallowed whole with liquid and must not be broken or chewed to ensure proper delivery of the active ingredients. The tablets may be taken with or without food.

Population-Specific Use

Dosing parameters vary for certain patient groups. For individuals with severe renal impairment (creatinine clearance less than 30 mL/min), the maximum dose is reduced to two tablets every 12 hours. Furthermore, use is restricted in severe hepatic impairment, and the dosing interval must be extended for patients over 75 years of age. Adherence to the instruction prohibiting co-administration with any other tramadol or acetaminophen-containing product is mandatory.

Research evidence / Overview of studies

The following sections summarize the types of studies and research findings that have explored the use of the study treatment.

Overview of Study Design

Research examined how the study treatment was administered and monitored. Studies reviewed populations with mild to moderate disease. The primary study design included randomized, placebo-controlled trials. These trials assessed short-term and intermediate-term effects (up to 24 weeks).

Key Areas of Research

Research has investigated the biological processes targeted by the study treatment.

Efficacy and Symptom Relief

Clinical research evaluated whether the treatment was associated with changes in joint mobility and stiffness in adult patients. Another study evaluated whether the treatment was associated with a reduction in inflammation in the affected joints. This finding was one of the factors examined in the research.

Studies examined whether the treatment was associated with a reduction in pain and swelling. Additionally, research evaluated the duration of effect on symptoms across various patient subgroups. The majority of studies focused on patients whose condition did not respond to initial standard treatments.

Long-Term Use and Combination Therapy

The longest studies assessing the parameters measured in the trials ran for up to one year. Dosing regimens explored in studies included various titration schedules.

Research is ongoing to evaluate whether the combination is associated with differences in long-term outcomes when compared to the study treatment alone. One of the initial studies reported findings when the study treatment was co-administered with a standard-of-care medication.

Safety and Side Effects Research

Research continues to explore the full safety profile and potential interactions.

Key Studies & References

1. Efficacy and Safety of Dologesic in Mild to Moderate Disease: A 24-Week Randomized Controlled Trial

Common questions about Dologesic (FAQ)

Q: What is Dologesic used to treat?

According to the official product information, Dologesic is indicated for the short-term treatment of moderate to severe acute pain. It is used in situations where other forms of pain relief are not considered appropriate or have not been effective. Regulatory documents indicate the medicine is intended to manage pain that occurs suddenly and is typically used for a limited duration.

Q: How long does it take for Dologesic to start working?

Official information indicates that Dologesic generally begins to relieve pain relatively quickly following administration. The onset of action is typically fast. Its generally rapid onset of action aligns with its use for the short-term relief of acute pain.

Q: Can Dologesic be used for chronic pain?

Regulatory documents specify that Dologesic is approved only for the short-term management of acute pain. Acute pain is temporary, while chronic pain is long-term. Official documentation specifies that it is not indicated or approved for the long-term management of chronic pain.

Q: Is Dologesic addictive?

As an opioid medication, official sources caution that Dologesic has the potential for dependence and abuse. Dependence is when the body adapts to the medicine. For this reason, official product labeling emphasizes that its use is restricted to short-term treatment.

Q: What are the common signs of an allergic reaction to Dologesic?

Official information mentions that signs of a serious allergic reaction, known as anaphylaxis, include swelling of the face, tongue, and throat, difficulty breathing, or a severe skin rash. These effects are considered uncommon but serious. Should these symptoms occur, official guidance states that immediate medical attention should be sought.

Official Storage and Disposal Guidelines

Storage and disposal requirements for Dologesic are established in regulatory documents to maintain product integrity and ensure public safety.

These mandated conditions ensure the medication remains stable and effective until its expiration date and safeguard against accidental ingestion.